miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 28, 2026

Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback

View original at finance.yahoo.com
Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback Never miss an important update on your stock portfolio and cut through the noise…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AstraZeneca currently scores 3 out of 6 on Simply Wall St's valuation checks, meaning the company screens as undervalued on half of the tests used

    60% confidence

  • The DCF model points to an estimated intrinsic value of £242.86 per share compared with the current share price of £143.02, implying shares trade at a 41.1% discount to fair value

    60% confidence

  • AstraZeneca is undervalued by 41.1% according to Discounted Cash Flow analysis

    60% confidence

Data points we hold from this source

AstraZeneca AB · free cash flow projected20.2 USD
AstraZeneca AB · intrinsic value per share242.86 GBP
AstraZeneca AB · stock return 1 month-6.0 percent
AstraZeneca AB · stock return 1 week2.9 percent
AstraZeneca AB · stock return 1 year27.5 percent
AstraZeneca AB · stock return 3 year35.2 percent
AstraZeneca AB · stock return 5 year121.6 percent
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback — Source | Via News | es.VIA.NEWS